[HTML][HTML] Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
The pharmacological treatment of dyslipidemia, a major modifiable risk factor for develo**
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …
Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute …
KA Krychtiuk, I Ahrens, H Drexel… - … Heart Journal: Acute …, 2022 - academic.oup.com
After experiencing an acute coronary syndrome (ACS), patients are at a high risk of suffering
from recurrent ischaemic cardiovascular events, especially in the very early phase. Low …
from recurrent ischaemic cardiovascular events, especially in the very early phase. Low …
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial
SJ Nicholls, M Ditmarsch, JJ Kastelein, SP Rigby… - Nature medicine, 2022 - nature.com
Global guidelines for the management of high-cardiovascular-risk patients include
aggressive goals for low-density lipoprotein cholesterol (LDL-C). Statin therapy alone is …
aggressive goals for low-density lipoprotein cholesterol (LDL-C). Statin therapy alone is …
Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models
RG Lee, AM Mazzola, MC Braun, C Platt, SB Vafai… - Circulation, 2023 - Am Heart Assoc
Background: VERVE-101 is an investigational in vivo CRISPR base-editing medicine
designed to alter a single DNA base in the PCSK9 gene, permanently turn off hepatic …
designed to alter a single DNA base in the PCSK9 gene, permanently turn off hepatic …
Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616
Background MK-0616 is an oral macrocyclic peptide inhibitor of proprotein convertase
subtilisin/kexin type 9 (PCSK9) in development for the treatment of hypercholesterolemia …
subtilisin/kexin type 9 (PCSK9) in development for the treatment of hypercholesterolemia …
High-intensity statin use among patients with atherosclerosis in the US
Background Preventive therapy among patients with established atherosclerotic
cardiovascular disease (ASCVD) is generally underused. Whether new guideline …
cardiovascular disease (ASCVD) is generally underused. Whether new guideline …
[HTML][HTML] Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and …
Background Obicetrapib, a novel, selective cholesteryl ester transfer protein (CETP)
inhibitor, reduces low-density lipoprotein cholesterol (LDL-C), LDL particles, apolipoprotein …
inhibitor, reduces low-density lipoprotein cholesterol (LDL-C), LDL particles, apolipoprotein …
Obicetrapib: reversing the tide of CETP inhibitor disappointments
JJP Kastelein, A Hsieh, MR Dicklin… - Current Atherosclerosis …, 2024 - Springer
Abstract Purpose of Review To discuss the history of cardiovascular outcomes trials of
cholesteryl ester transfer protein (CETP) inhibitors and to describe obicetrapib, a next …
cholesteryl ester transfer protein (CETP) inhibitors and to describe obicetrapib, a next …
Advances in treatment of dyslipidemia
J Dybiec, W Baran, B Dąbek, P Fularski… - International Journal of …, 2023 - mdpi.com
Dyslipidemias have emerged as prevalent disorders among patients, posing significant risks
for the development and progression of cardiovascular diseases. These conditions are …
for the development and progression of cardiovascular diseases. These conditions are …
Aggressive LDL-C lowering and the brain: impact on risk for dementia and hemorrhagic stroke: a scientific statement from the American Heart Association
The objective of this scientific statement is to evaluate contemporary evidence that either
supports or refutes the conclusion that aggressive low-density lipoprotein cholesterol …
supports or refutes the conclusion that aggressive low-density lipoprotein cholesterol …